Compugen Future Growth

Future criteria checks 2/6

Compugen's earnings are forecast to decline at 10.1% per annum while its annual revenue is expected to grow at 21.7% per year. EPS is expected to decline by 4.9% per annum.

Key information

-10.1%

Earnings growth rate

-4.9%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	21.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Mar 2024

Recent future growth updates

Recent updates

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Compugen Q3 Earnings Preview

Nov 04

Earnings and Revenue Growth Forecasts

NasdaqCM:CGEN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	29	-49	-30	-28	2
12/31/2025	35	-29	-16	-14	2
12/31/2024	38	-13	43	43	2
12/31/2023	33	-19	-36	-36	N/A
9/30/2023	8	-32	N/A	N/A	N/A
6/30/2023	8	-33	-33	-32	N/A
3/31/2023	8	-33	N/A	N/A	N/A
12/31/2022	8	-34	-35	-34	N/A
9/30/2022	N/A	-39	N/A	N/A	N/A
6/30/2022	6	-34	-30	-30	N/A
3/31/2022	6	-34	N/A	N/A	N/A
12/31/2021	6	-34	-23	-23	N/A
9/30/2021	8	-34	N/A	N/A	N/A
6/30/2021	2	-36	-31	-30	N/A
3/31/2021	2	-32	N/A	N/A	N/A
12/31/2020	2	-30	-28	-28	N/A
9/30/2020	N/A	-28	N/A	N/A	N/A
6/30/2020	N/A	-26	-23	-23	N/A
3/31/2020	N/A	-26	N/A	N/A	N/A
12/31/2019	N/A	-27	-28	-28	N/A
9/30/2019	N/A	-30	N/A	N/A	N/A
6/30/2019	8	-27	-22	-22	N/A
3/31/2019	8	-31	N/A	N/A	N/A
12/31/2018	18	-23	-13	-13	N/A
9/30/2018	18	-23	N/A	N/A	N/A
6/30/2018	10	-29	-24	-23	N/A
3/31/2018	10	-28	N/A	N/A	N/A
12/31/2017	N/A	-37	-31	-31	N/A
9/30/2017	0	-36	N/A	N/A	N/A
6/30/2017	0	-34	N/A	-27	N/A
3/31/2017	1	-32	N/A	N/A	N/A
12/31/2016	1	-32	N/A	-20	N/A
9/30/2016	9	-23	N/A	N/A	N/A
6/30/2016	9	-22	N/A	-20	N/A
3/31/2016	9	-23	N/A	N/A	N/A
12/31/2015	9	-20	N/A	-26	N/A
9/30/2015	8	-21	N/A	N/A	N/A
6/30/2015	9	-20	N/A	-17	N/A
3/31/2015	11	-15	N/A	N/A	N/A
12/31/2014	12	-11	N/A	-11	N/A
9/30/2014	8	-13	N/A	N/A	N/A
6/30/2014	7	-12	N/A	-7	N/A
3/31/2014	6	-13	N/A	N/A	N/A
12/31/2013	4	-14	N/A	-6	N/A
9/30/2013	2	-17	N/A	N/A	N/A
6/30/2013	0	-15	N/A	-12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CGEN's revenue (21.7% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: CGEN's revenue (21.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CGEN's Return on Equity is forecast to be high in 3 years time

Compugen Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 41%, EPS downgraded

Consensus revenue estimates fall by 45%

Consensus EPS estimates upgraded to US$0.31 loss

Price target decreased by 7.0% to US$5.50

Price target increased by 15% to US$6.80

Price target decreased to US$6.29

Recent updates

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%, EPS downgraded

Now 23% undervalued

New major risk - Revenue and earnings growth

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Compugen Ltd. Announces Executive Changes

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 45%

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer

Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Insufficient new directors

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.31 loss

Compugen Ltd., Annual General Meeting, Sep 20, 2023

Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 7.0% to US$5.50

Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 15% to US$6.80

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023

Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

Price target decreased to US$6.29

Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

Compugen Announces Receipt of Nasdaq Delisting Notice

Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen appoints Alberto Sessa as CFO

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Compugen Ltd. Announces Resignation of Ari Krashin as Chief Operating Officer in August 2022

Compugen Q2 2022 Earnings Preview

Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Announces CFO Departure

Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$14.00

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Board Changes

Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$18.57

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

High number of new directors

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

Senior VP & Chief Medical Officer notifies of intention to sell stock

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Compugen Ltd. Updates Data from Phase 1 Study of COM701

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy

Compugen's COM902 demonstrates potential benefit in cancer

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Analysts update estimates

Earnings miss expectations

Compugen Ltd. Announces Data Update from Com701 Phase 1 Clinical Trial

New 90-day low: US$10.51